Investigational Drug Information for Gaboxadol
✉ Email this page to a colleague
What is the development status for investigational drug Gaboxadol?
Gaboxadol is an investigational drug.
There have been 20 clinical trials for Gaboxadol.
The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2004.
The most common disease conditions in clinical trials are Sleep Initiation and Maintenance Disorders, Syndrome, and Angelman Syndrome. The leading clinical trial sponsors are H. Lundbeck A/S, Ovid Therapeutics Inc., and [disabled in preview].
Summary for Gaboxadol
US Patents | 0 |
International Patents | 0 |
US Patent Applications | 675 |
WIPO Patent Applications | 352 |
Japanese Patent Applications | 156 |
Clinical Trial Progress | Phase 3 (2004-10-01) |
Vendors | 45 |
Recent Clinical Trials for Gaboxadol
Title | Sponsor | Phase |
---|---|---|
A Study of OV101 in Individuals With Angelman Syndrome (AS) | Ovid Therapeutics Inc. | Phase 3 |
An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome | Ovid Therapeutics Inc. | Phase 2 |
A Study of OV101 in Individuals With Fragile X Syndrome | Ovid Therapeutics Inc. | Phase 2 |
Clinical Trial Summary for Gaboxadol
Top disease conditions for Gaboxadol
Top clinical trial sponsors for Gaboxadol
US Patents for Gaboxadol
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |